We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+23.46%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$39.5M
Cap. Flow
+$14.4M
Cap. Flow %
3.63%
Top 10 Hldgs %
92.38%
Holding
28
New
1
Increased
3
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$31M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$407K
3
RZLT icon
Rezolute
RZLT
+$222K
4
KRYS icon
Krystal Biotech
KRYS
+$147K

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$5.54M
2
CYTK icon
Cytokinetics
CYTK
+$4.02M
3
LEGN icon
Legend Biotech
LEGN
+$2.59M
4
BNTX icon
BioNTech
BNTX
+$1.82M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$1.08M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.41B
$166M 41.84%
6,371,669
– –
AARD
2
Aardvark Therapeutics
AARD
$140M
$53M 13.38%
3,917,299
– –
NUVB icon
3
Nuvation Bio
NUVB
$2.33B
$50.6M 12.78%
25,954,439
– –
UPB
4
Upstream Bio Inc
UPB
$348M
$36.1M 9.11%
3,285,293
– –
NAMS icon
5
NewAmsterdam Pharma
NAMS
$3.27B
$13.9M 3.52%
770,000
– –
BYSI icon
6
BeyondSpring
BYSI
$48.7M
$10.6M 2.69%
4,531,481
-351,170
-7% -$649K
MRUS
7
DELISTED
Merus
MRUS
$9.95M 2.51%
189,098
– –
KRYS icon
8
Krystal Biotech
KRYS
$10.7B
$9.07M 2.29%
66,000
+1,000
+2% +$147K
MLTX icon
9
MoonLake Immunotherapeutics
MLTX
$1.59B
$8.57M 2.16%
181,600
+10,000
+6% +$407K
RVMD icon
10
Revolution Medicines
RVMD
$39.1B
$8.31M 2.1%
226,000
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$744M
$5.74M 1.45%
4,041,736
– –
LYEL icon
12
Lyell Immunopharma
LYEL
$318M
$5.26M 1.33%
595,466
-1
-0% -$9
ACLX
13
DELISTED
Arcellx
ACLX
$4.46M 1.13%
547,609
+497,609
+995% +$31M
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.11M 1.04%
143,000
-34,958
-20% -$1.08M
AURA icon
15
Aura Biosciences
AURA
$729M
$3.23M 0.82%
515,555
– –
ZNTL icon
16
Zentalis Pharmaceuticals
ZNTL
$329M
$1.54M 0.39%
1,323,327
-696,435
-34% -$919K
EQ icon
17
Equillium
EQ
$147M
$1.4M 0.35%
4,447,308
– –
FDMT icon
18
4D Molecular Therapeutics
FDMT
$515M
$889K 0.22%
239,510
-96,005
-29% -$337K
RCUS icon
19
Arcus Biosciences
RCUS
$3.4B
$811K 0.2%
160,000
-648,789
-80% -$5.54M
ILMN icon
20
Illumina
ILMN
$29.2B
$761K 0.19%
7,979
-3,770
-32% -$306K
LEGN icon
21
Legend Biotech
LEGN
$3.68B
$710K 0.18%
20,000
-80,000
-80% -$2.59M
GRAL
22
GRAIL Inc
GRAL
$2.76B
$498K 0.13%
9,684
– –
PYXS icon
23
Pyxis Oncology
PYXS
$184M
$359K 0.09%
326,810
– –
RZLT icon
24
Rezolute
RZLT
$474M
$267K 0.07%
+59,900
New +$222K
NUVB.WS
25
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$127K 0.03%
646,057
– –
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Decheng Capital held 28 positions worth $396M, up 11% from $356M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Decheng Capital deployed $14.4M of net new capital in Q2 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Rezolute: 59,900 shares worth $267K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $5.54M trimmed.

  • Decheng Capital's largest Q2 2025 buy was Rezolute: 59,900 shares worth $267K.
  • Decheng Capital added most to Arcellx in Q2 2025, an estimated $31M increase.
  • Decheng Capital's biggest Q2 2025 reduction was Arcus Biosciences, cutting an estimated $5.54M.
  • Decheng Capital fully exited Cytokinetics in Q2 2025, selling an estimated $4.02M.
  • Decheng Capital's ten largest holdings make up 92% of its $396M portfolio in Q2 2025.
  • Decheng Capital opened 1 new position and closed 3 in Q2 2025.
  • Decheng Capital's portfolio value rose 11% quarter-over-quarter to $396M.

Based on Decheng Capital's 13F filing for Q2 2025, filed 13 Aug 2025.